MedPath

Glycemic Excursion Minimization (GEM) to Outshine Health Disparities

Not Applicable
Recruiting
Conditions
Type 2 Diabetes
Registration Number
NCT06236581
Lead Sponsor
Catherine Davis
Brief Summary

The purpose of this study is to see if the GEM intervention is acceptable and helpful to Black adults with type 2 diabetes. The GEM intervention (coaching to reduce carbohydrate intake and increase physical activity after meals, with feedback from a continuous glucose monitor, CGM) might improve blood glucose levels, reduce diabetes distress, and increase empowerment and confidence in managing diabetes.

Detailed Description

The purpose of the study is to test the feasibility, acceptability, and initial efficacy of the tailored GEM intervention among adult Black patients with type 2 diabetes, who are not on insulin or secretagogues.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
25
Inclusion Criteria
  • type 2 diabetes
  • capable of making dietary and physical activity changes
Exclusion Criteria
  • on insulin or secretagogue
  • on medications that impede weight loss (e.g., prednisone)
  • pregnant or planning pregnancy in the next 2 months
  • no history of moderate to severe hypoglycemia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from baseline on percent time in range from continuous glucose monitor at post-interventionBaseline week and post-intervention week. From baseline week to the week after end of intervention or waitlist period, up to 6 weeks

Difference in percent of time in range (70-180 mg/dL) from continuous glucose monitor data. Change = post intervention week minus baseline week.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Georgia Prevention Institute

🇺🇸

Augusta, Georgia, United States

Georgia Prevention Institute
🇺🇸Augusta, Georgia, United States
Andre Soares, PT MS
Contact
706-721-4534
Catherine L Davis, PhD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.